| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
University of Melbourne, Department of Surgery, Royal Melbourne Hospital, Victoria, Australia;
Cardiovascular Biology Laboratory, Harvard School of Public Health, and
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; and
§
Monash Medical School, Alfred Hospital, Prahran, Australia
To study the role of IL-4 in tolerance induction and transplant
arteriosclerosis, BALB/c hearts were transplanted into C57BL/6J
wild-type or IL-4 knockout (IL-4-/-) recipients. A
30-day course of anti-CD4/8 mAb was used to induce long term graft
survival. Primary graft survival was 50% (5 of 10) in
IL-4-/- recipients comparable to 63% (5 of 8) in
wild-type recipients. Mice with allografts surviving >80 days were
tested for tolerance by challenge with a second donor or third party
(CBA) heart. Secondary donor-strain heart grafts survived >30 days,
but showed histologic evidence of ongoing alloimmune response. Third
party hearts rejected rapidly. Although immunostaining and
32P RT-PCR assays showed no differences in the mononuclear
cell infiltration and T cell activation between IL-4-/-
and wild-type tolerant recipients, some monokines (IL-12, TNF-
, and
allograft inflammatory factor-1) were up-regulated in grafts from
IL-4-/- recipients. Computer-assisted analysis of
elastin-stained vessels revealed that the severity of vascular
thickening (percentage of luminal occlusion, mean ± SD,
n = 329) was similar in grafts from
IL-4-/- (63.7 ± 16.9%) and wild-type (69.5 ±
17.6%) recipients. Thus, IL-4 deficiency did not alter primary or
secondary graft survival, infiltration, or vascular thickening. The
selective alterations in monokine expression suggests that alternative
pathways are activated and may compensate in IL-4-/-
mice.
This article has been cited by other articles:
|
|
 |
|
  H. Kosuge, J.-i. Suzuki, T. Kakuta, G. Haraguchi, N. Koga, H. Futamatsu, R. Gotoh, M. Inobe, M. Isobe, and T. Uede Attenuation of Graft Arterial Disease by Manipulation of the LIGHT Pathway Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1409 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassalli, S. Fleury, J. Li, J.-J. Goy, L. Kappenberger, and L. K. von Segesser Gene transfer of cytoprotective and immunomodulatory molecules for prevention of cardiac allograft rejection Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zhou, G. L. Szot, Z. Guo, O. Kim, G. He, J. Wang, M. J. Grusby, K. A. Newell, J. R. Thistlethwaite, J. A. Bluestone, et al. Role of STAT4 and STAT6 Signaling in Allograft Rejection and CTLA4-Ig-Mediated Tolerance J. Immunol., November 15, 2000; 165(10): 5580 - 5587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimizu, U. Schonbeck, F. Mach, P. Libby, and R. N. Mitchell Host CD40 Ligand Deficiency Induces Long-Term Allograft Survival and Donor-Specific Tolerance in Mouse Cardiac Transplantation But Does Not Prevent Graft Arteriosclerosis J. Immunol., September 15, 2000; 165(6): 3506 - 3518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Furukawa, D. A. Mandelbrot, P. Libby, A. H. Sharpe, and R. N. Mitchell Association of B7-1 Co-Stimulation with the Development of Graft Arterial Disease : Studies Using Mice Lacking B7-1, B7-2, or B7-1/B7-2 Am. J. Pathol., August 1, 2000; 157(2): 473 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koglin, T. Glysing-Jensen, S. Gadiraju, and M. E. Russell Attenuated Cardiac Allograft Vasculopathy in Mice With Targeted Deletion of the Transcription Factor STAT4 Circulation, March 7, 2000; 101(9): 1034 - 1039. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
